Volume 25, Issue 1
January 2023
Cover image
Cover image
Panels from Figure 2 of the SNO consensus review by Miller and Gonzalez Castro et al. “Isocitrate dehydrogenase (IDH) mutant gliomas: a Society for Neuro-Oncology (SNO) consensus review on diagnosis, management, and future directions” beginning on p. 4.
ISSN 1522-8517
EISSN 1523-5866
Issue navigation
Volume 25, Issue 1, January 2023
Editorial
Negative trials over and over again: How can we do better?
Neuro-Oncology, Volume 25, Issue 1, January 2023, Pages 1–3, https://doi.org/10.1093/neuonc/noac226
Consensus Review
Isocitrate dehydrogenase (IDH) mutant gliomas: A Society for Neuro-Oncology (SNO) consensus review on diagnosis, management, and future directions
Neuro-Oncology, Volume 25, Issue 1, January 2023, Pages 4–25, https://doi.org/10.1093/neuonc/noac207
Editorial
Optimize treatment approaches in isocitrate dehydrogenase (IDH) mutant gliomas: open issues
Neuro-Oncology, Volume 25, Issue 1, January 2023, Pages 26–27, https://doi.org/10.1093/neuonc/noac227
Review
Translational significance of CDKN2A/B homozygous deletion in isocitrate dehydrogenase-mutant astrocytoma
Neuro-Oncology, Volume 25, Issue 1, January 2023, Pages 28–36, https://doi.org/10.1093/neuonc/noac205
Guidelines
European Association of Neuro-Oncology (EANO) guidelines for treatment of primary central nervous system lymphoma (PCNSL)
Neuro-Oncology, Volume 25, Issue 1, January 2023, Pages 37–53, https://doi.org/10.1093/neuonc/noac196
Basic and Translational Investigations
Therapeutic targeting of prenatal pontine ID1 signaling in diffuse midline glioma
Neuro-Oncology, Volume 25, Issue 1, January 2023, Pages 54–67, https://doi.org/10.1093/neuonc/noac141
Clinical significance and molecular annotation of cellular morphometric subtypes in lower-grade gliomas discovered by machine learning
Neuro-Oncology, Volume 25, Issue 1, January 2023, Pages 68–81, https://doi.org/10.1093/neuonc/noac154
Oct4A palmitoylation modulates tumorigenicity and stemness in human glioblastoma cells
Neuro-Oncology, Volume 25, Issue 1, January 2023, Pages 82–96, https://doi.org/10.1093/neuonc/noac157
Novel cancer gene discovery using a forward genetic screen in RCAS-PDGFB-driven gliomas
Neuro-Oncology, Volume 25, Issue 1, January 2023, Pages 97–107, https://doi.org/10.1093/neuonc/noac158
Recovery from the damage of cranial radiation modulated by memantine, an NMDA receptor antagonist, combined with hyperbaric oxygen therapy
Neuro-Oncology, Volume 25, Issue 1, January 2023, Pages 108–122, https://doi.org/10.1093/neuonc/noac162
Clinical Investigations
Radiotherapy combined with nivolumab or temozolomide for newly diagnosed glioblastoma with unmethylated MGMT promoter: An international randomized phase III trial
Neuro-Oncology, Volume 25, Issue 1, January 2023, Pages 123–134, https://doi.org/10.1093/neuonc/noac099
Editorial
The road we travel
Neuro-Oncology, Volume 25, Issue 1, January 2023, Pages 135–136, https://doi.org/10.1093/neuonc/noac235
Clinical Investigations
Low-risk meningioma: Initial outcomes from NRG Oncology/RTOG 0539
Neuro-Oncology, Volume 25, Issue 1, January 2023, Pages 137–145, https://doi.org/10.1093/neuonc/noac137
Olutasidenib (FT-2102) in patients with relapsed or refractory IDH1-mutant glioma: A multicenter, open-label, phase Ib/II trial
Neuro-Oncology, Volume 25, Issue 1, January 2023, Pages 146–156, https://doi.org/10.1093/neuonc/noac139
Trastuzumab deruxtecan in patients with central nervous system involvement from HER2-positive breast cancer: The DEBBRAH trial
Neuro-Oncology, Volume 25, Issue 1, January 2023, Pages 157–166, https://doi.org/10.1093/neuonc/noac144
Hippocampal avoidance prophylactic cranial irradiation (HA-PCI) for small cell lung cancer reduces hippocampal atrophy compared to conventional PCI
Neuro-Oncology, Volume 25, Issue 1, January 2023, Pages 167–176, https://doi.org/10.1093/neuonc/noac148
Diversity within the neurosurgical oncology workforce in the United States: A cross-sectional study with proposed strategies to pave the path forward
Neuro-Oncology, Volume 25, Issue 1, January 2023, Pages 177–184, https://doi.org/10.1093/neuonc/noac150
Pediatric Neuro-Oncology
Activation of Hedgehog signaling by the oncogenic RELA fusion reveals a primary cilia-dependent vulnerability in supratentorial ependymoma
Neuro-Oncology, Volume 25, Issue 1, January 2023, Pages 185–198, https://doi.org/10.1093/neuonc/noac147
Multi-institutional study of the frequency, genomic landscape, and outcome of IDH-mutant glioma in pediatrics
Neuro-Oncology, Volume 25, Issue 1, January 2023, Pages 199–210, https://doi.org/10.1093/neuonc/noac132
Erratum
Erratum to: Characterizing the biology of primary brain tumors and their microenvironment via single-cell profiling methods
Neuro-Oncology, Volume 25, Issue 1, January 2023, Page 211, https://doi.org/10.1093/neuonc/noac257
Corrigenda
Corrigendum to: Palliative care and end-of-life care in adults with malignant brain tumors
Neuro-Oncology, Volume 25, Issue 1, January 2023, Page 212, https://doi.org/10.1093/neuonc/noac252
Corrigendum to: EGFR, the Lazarus target for precision oncology in glioblastoma
Neuro-Oncology, Volume 25, Issue 1, January 2023, Page 213, https://doi.org/10.1093/neuonc/noac254
Reviewer Lists
Reviewer Lists
Neuro-Oncology, Volume 25, Issue 1, January 2023, Pages 214–216, https://doi.org/10.1093/neuonc/noac277
Society News
Forthcoming Meetings
Neuro-Oncology, Volume 25, Issue 1, January 2023, Page 217, https://doi.org/10.1093/neuonc/noac259
